The association of genetic factors with serum calretinin levels in asbestos-related diseases

1. Chapman SJ, Cookson WO, Musk AW, Lee YC. Benign asbestos pleural diseases. Curr Opin Pulm Med 2003; 9: 266–71. doi: 10.1097/00063198-200307000-00004 ChapmanSJ CooksonWO MuskAW LeeYC Benign asbestos pleural diseases Curr Opin Pulm Med 2003 9 266 71 10.1097/00063198-200307000-00004 Open DOISearch in Google Scholar

2. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos. IARC Monogr Eval Carcinog Risk Chem Man 1977; 14: 1–106. PMID: 863456 IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos IARC Monogr Eval Carcinog Risk Chem Man 1977 14 1 106 863456 Search in Google Scholar

3. Weiner SJ, Neragi-Miandoab S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Cancer Res Clin Oncol 2009; 135: 15–27. doi: 10.1007/s00432-008-0444-9 WeinerSJ Neragi-MiandoabS Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors J Cancer Res Clin Oncol 2009 135 15 27 10.1007/s00432-008-0444-9 Open DOISearch in Google Scholar

4. Melaiu O, Gemignani F, Landi S. The genetic susceptibility in the development of malignant pleural mesothelioma. J Thorac Dis 2018; 10: S246–52. doi: 10.21037/jtd.2017.10.41 MelaiuO GemignaniF LandiS The genetic susceptibility in the development of malignant pleural mesothelioma J Thorac Dis 2018 10 S246 52 10.21037/jtd.2017.10.41 Open DOISearch in Google Scholar

5. Pylkkänen L, Sainio M, Ollikainen T, Mattson K, Nordling S, Carpén O, et al. Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncol Rep 2002; 9: 955–9. doi: 10.3892/or.9.5.955 PylkkänenL SainioM OllikainenT MattsonK NordlingS CarpénO Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region Oncol Rep 2002 9 955 9 10.3892/or.9.5.955 Open DOISearch in Google Scholar

6. Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999; 180: 150–7. doi: 10.1002/(sici)1097-4652(199908)180:2<150::Aidjcp2>3.0.Co;2-h MurthySS TestaJR Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma J Cell Physiol 1999 180 150 7 10.1002/(sici)1097-4652(199908)180:2<150::Aidjcp2>3.0.Co;2-h Open DOISearch in Google Scholar

7. Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136–44. doi: 10.2478/v10019-012-0032-0 KovacV ZwitterM ZagarT Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients Radiol Oncol 2012 46 136 44 10.2478/v10019-012-0032-0 Open DOISearch in Google Scholar

8. Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, et al. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer 2017; 17: 386. doi: 10.1186/s12885-017-3375-5 JohnenG GawrychK RaikoI CasjensS PeschB WeberDG Calretinin as a blood-based biomarker for mesothelioma BMC Cancer 2017 17 386 10.1186/s12885-017-3375-5 Open DOISearch in Google Scholar

9. Carbone M, Adusumilli PS, Alexander HR, Jr., Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 2019; 69: 402–29. doi: 10.3322/caac.21572 CarboneM AdusumilliPS AlexanderHRJr. BaasP BardelliF BononiA Mesothelioma: scientific clues for prevention, diagnosis, and therapy CA Cancer J Clin 2019 69 402 29 10.3322/caac.21572 Open DOISearch in Google Scholar

10. Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018; 142: 89–108. doi: 10.5858/arpa.2017-0124-RA HusainAN ColbyTV OrdóñezNG AllenTC AttanoosRL BeasleyMB Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group Arch Pathol Lab Med 2018 142 89 108 10.5858/arpa.2017-0124-RA Open DOISearch in Google Scholar

11. Rogers JH. Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons. J Cell Biol 1987; 105: 1343–53. doi: 10.1083/jcb.105.3.1343. RogersJH Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons J Cell Biol 1987 105 1343 53 10.1083/jcb.105.3.1343 Open DOISearch in Google Scholar

12. Worthmuller J, Blum W, Pecze L, Salicio V, Schwaller B. Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway. Oncotarget 2018; 9: 36256–72. doi: 10.18632/oncotarget.26332 WorthmullerJ BlumW PeczeL SalicioV SchwallerB Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway Oncotarget 2018 9 36256 72 10.18632/oncotarget.26332 Open DOISearch in Google Scholar

13. Parmentier M, Passage E, Vassart G, Mattei MG. The human calbindin D28k (CALB1) and calretinin (CALB2) genes are located at 8q21.3----q22.1 and 16q22----q23, respectively, suggesting a common duplication with the carbonic anhydrase isozyme loci. Cytogenet Cell Genet 1991; 57: 41–3. doi: 10.1159/000133111 ParmentierM PassageE VassartG MatteiMG The human calbindin D28k (CALB1) and calretinin (CALB2) genes are located at 8q21.3----q22.1 and 16q22----q23, respectively, suggesting a common duplication with the carbonic anhydrase isozyme loci Cytogenet Cell Genet 1991 57 41 3 10.1159/000133111 Open DOISearch in Google Scholar

14. Cristaudo A, Bonotti A, Guglielmi G, Fallahi P, Foddis R. Serum mesothelin and other biomarkers: what have we learned in the last decade? J Thorac Dis 2018; 10: S353–9. doi: 10.21037/jtd.2017.10.132 CristaudoA BonottiA GuglielmiG FallahiP FoddisR Serum mesothelin and other biomarkers: what have we learned in the last decade? J Thorac Dis 2018 10 S353 9 10.21037/jtd.2017.10.132 Open DOISearch in Google Scholar

15. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 1541–9. doi: 10.1200/JCO.2011.39.6671 HollevoetK ReitsmaJB CreaneyJ GrigoriuBD RobinsonBW ScherpereelA Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis J Clin Oncol 2012 30 1541 9 10.1200/JCO.2011.39.6671 Open DOISearch in Google Scholar

16. Raiko I, Sander I, Weber DG, Raulf-Heimsoth M, Gillissen A, Kollmeier J, et al. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer 2010; 10: 242. doi: 10.1186/1471-2407-10-242 RaikoI SanderI WeberDG Raulf-HeimsothM GillissenA KollmeierJ Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients BMC Cancer 2010 10 242 10.1186/1471-2407-10-242 Open DOISearch in Google Scholar

17. Aguilar-Madrid G, Pesch B, Calderón-Aranda ES, Burek K, Jiménez-Ramírez C, Juárez-Pérez CA, et al. Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population. Int J Med Sci 2018; 15: 883–91. doi: 10.7150/ijms.23939 Aguilar-MadridG PeschB Calderón-ArandaES BurekK Jiménez-RamírezC Juárez-PérezCA Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population Int J Med Sci 2018 15 883 91 10.7150/ijms.23939 Open DOISearch in Google Scholar

18. Jiménez-Ramírez C, Casjens S, Juárez-Pérez CA, Raiko I, Del Razo LM, Taeger D, et al. Mesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesothelioma. Lung 2019; 197: 641–9. doi: 10.1007/s00408-019-00244-1 Jiménez-RamírezC CasjensS Juárez-PérezCA RaikoI Del RazoLM TaegerD Mesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesothelioma Lung 2019 197 641 9 10.1007/s00408-019-00244-1 Open DOISearch in Google Scholar

19. Li D, Wang B, Long H, Wen F. Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis. Sci Rep 2015; 5: 9507. doi: 10.1038/srep09507 LiD WangB LongH WenF Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis Sci Rep 2015 5 9507 10.1038/srep09507 Open DOISearch in Google Scholar

20. Lehnert M, Weber DG, Taeger D, Raiko I, Kollmeier J, Stephan-Falkenau S, et al. Determinants of plasma calretinin in patients with malignant pleural mesothelioma. BMC Res Notes 2020; 13: 359. doi: 10.1186/s13104-020-05187-y LehnertM WeberDG TaegerD RaikoI KollmeierJ Stephan-FalkenauS Determinants of plasma calretinin in patients with malignant pleural mesothelioma BMC Res Notes 2020 13 359 10.1186/s13104-020-05187-y Open DOISearch in Google Scholar

21. Zupanc C, Franko A, Štrbac D, Dodič Fikfak M, Kovač V, Dolžan V, et al. Serum calretinin as a biomarker in malignant mesothelioma. J Clin Med 2021; 10: 4875. doi: 10.3390/jcm10214875 ZupancC FrankoA ŠtrbacD Dodič FikfakM KovačV DolžanV Serum calretinin as a biomarker in malignant mesothelioma J Clin Med 2021 10 4875 10.3390/jcm10214875 Open DOISearch in Google Scholar

22. Casjens S, Weber DG, Johnen G, Raiko I, Taeger D, Meinig C, et al. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study. BMJ Open 2017; 7: e017104. doi: 10.1136/bmjopen-2017-017104 CasjensS WeberDG JohnenG RaikoI TaegerD MeinigC Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study BMJ Open 2017 7 e017104 10.1136/bmjopen-2017-017104 Open DOISearch in Google Scholar

23. Kresoja-Rakic J, Kapaklikaya E, Ziltener G, Dalcher D, Santoro R, Christensen BC, et al. Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells. Oncotarget 2016; 7: 21272–86. doi: 10.18632/oncotarget.7114 Kresoja-RakicJ KapaklikayaE ZiltenerG DalcherD SantoroR ChristensenBC Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells Oncotarget 2016 7 21272 86 10.18632/oncotarget.7114 Open DOISearch in Google Scholar

24. Blum W, Pecze L, Rodriguez JW, Steinauer M, Schwaller B. Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter. BMC Cancer 2018; 18: 475. doi: 10.1186/s12885-018-4385-7 BlumW PeczeL RodriguezJW SteinauerM SchwallerB Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter BMC Cancer 2018 18 475 10.1186/s12885-018-4385-7 Open DOISearch in Google Scholar

25. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147–52. doi: 10.1038/nature06487 TavazoieSF AlarconC OskarssonT PaduaD WangQ BosPD Endogenous human microRNAs that suppress breast cancer metastasis Nature 2008 451 147 52 10.1038/nature06487 Open DOISearch in Google Scholar

26. Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, et al. Posttranscriptional regulation controls calretinin expression in malignant pleural mesothelioma. Front Genet 2017; 8: 70. doi: 10.3389/fgene.2017.00070 Kresoja-RakicJ SulemaniM KirschnerMB RonnerM ReidG KaoS Posttranscriptional regulation controls calretinin expression in malignant pleural mesothelioma Front Genet 2017 8 70 10.3389/fgene.2017.00070 Open DOISearch in Google Scholar

27. Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V, Franko A. Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases. Radiol Oncol 2020; 54: 86–95. doi: 10.2478/raon-2020-0011 GoricarK KovacV Dodic-FikfakM DolzanV FrankoA Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases Radiol Oncol 2020 54 86 95 10.2478/raon-2020-0011 Open DOISearch in Google Scholar

28. Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, et al. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. J Thorac Oncol 2014; 9: 1662–8. doi: 10.1097/jto.0000000000000322 GarritanoS De SantiC SilvestriR MelaiuO CipolliniM BaroneE A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people J Thorac Oncol 2014 9 1662 8 10.1097/jto.0000000000000322 Open DOISearch in Google Scholar

29. De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, et al. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. Occup Environ Med 2017; 74: 456–63. doi: 10.1136/oemed-2016-104024 De SantiC PucciP BonottiA MelaiuO CipolliniM SilvestriR Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals Occup Environ Med 2017 74 456 63 10.1136/oemed-2016-104024 Open DOISearch in Google Scholar

30. Vonlanthen S, Kawecki TJ, Betticher DC, Pfefferli M, Schwaller B. Heterozygosity of SNP513 in intron 9 of the human calretinin gene (CALB2) is a risk factor for colon cancer. Anticancer Res 2007; 27: 4279–88. PMID: 18214032 VonlanthenS KaweckiTJ BetticherDC PfefferliM SchwallerB Heterozygosity of SNP513 in intron 9 of the human calretinin gene (CALB2) is a risk factor for colon cancer Anticancer Res 2007 27 4279 88 18214032 Search in Google Scholar

31. Tossavainen A. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 1997; 23: 311–6. doi: 10.5271/sjweh.226 TossavainenA Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution Scand J Work Environ Health 1997 23 311 6 10.5271/sjweh.226 Open DOISearch in Google Scholar

32. American Thoracic S. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170: 691–715. doi:10.1164/rccm.200310-1436ST American ThoracicS Diagnosis and initial management of nonmalignant diseases related to asbestos Am J Respir Crit Care Med 2004 170 691 715 10.1164/rccm.200310-1436ST Open DOISearch in Google Scholar

33. Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res 2018; 46: D296–302. doi: 10.1093/nar/gkx1067 ChouCH ShresthaS YangCD ChangNW LinYL LiaoKW miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions Nucleic Acids Res 2018 46 D296 302 10.1093/nar/gkx1067 Open DOISearch in Google Scholar

34. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37: W600-5. doi: 10.1093/nar/gkp290 XuZ TaylorJA SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies Nucleic Acids Res 2009 37 W600-5 10.1093/nar/gkp290 Open DOISearch in Google Scholar

35. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308–11. doi: 10.1093/nar/29.1.308 SherryST WardMH KholodovM BakerJ PhanL SmigielskiEM dbSNP: the NCBI database of genetic variation Nucleic Acids Res 2001 29 308 11 10.1093/nar/29.1.308 Open DOISearch in Google Scholar

36. Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PloS One 2012; 7: e50966. doi: 10.1371/journal.pone.0050966 SrivastavaK SrivastavaA Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk PloS One 2012 7 e50966 10.1371/journal.pone.0050966 Open DOISearch in Google Scholar

37. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012; 40: D930–4. doi: 10.1093/nar/gkr917 WardLD KellisM HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants Nucleic Acids Res 2012 40 D930 4 10.1093/nar/gkr917 Open DOISearch in Google Scholar

38. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45: 580–5. doi: 10.1038/ng.2653 The Genotype-Tissue Expression (GTEx) project Nat Genet 2013 45 580 5 10.1038/ng.2653 Open DOISearch in Google Scholar

39. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 2015; 31: 3555–7. doi: 10.1093/bioinformatics/btv402 MachielaMJ ChanockSJ LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants Bioinformatics 2015 31 3555 7 10.1093/bioinformatics/btv402 Open DOISearch in Google Scholar

40. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 1038–9. doi: 10.1093/bioinformatics/btm058 TregouetDA GarelleV A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies Bioinformatics 2007 23 1038 9 10.1093/bioinformatics/btm058 Open DOISearch in Google Scholar

41. Lehnert M, Weber DG, Taeger D, Raiko I, Kollmeier J, Stephan-Falkenau S, et al. Determinants of plasma calretinin in patients with malignant pleural mesothelioma. BMC Res Notes 2020; 13: 359. doi: 10.1186/s13104-020-05187-y LehnertM WeberDG TaegerD RaikoI KollmeierJ Stephan-FalkenauS Determinants of plasma calretinin in patients with malignant pleural mesothelioma BMC Res Notes 2020 13 359 10.1186/s13104-020-05187-y Open DOISearch in Google Scholar

42. Li L, Wang S, Zhang Y, Pan J. The E2F transcription factor 2: what do we know? Biosci Trends 2021; 15: 83–92. doi: 10.5582/bst.2021.01072 LiL WangS ZhangY PanJ The E2F transcription factor 2: what do we know? Biosci Trends 2021 15 83 92 10.5582/bst.2021.01072 Open DOISearch in Google Scholar

43. Guo AY, Zhai K, Xu JL, Hu JL, Gao L. Identification of a low-frequency mis-sense variant in E2F transcription factor 7 associated with colorectal cancer risk in a chinese population. Asian Pac J Cancer Prev 2017; 18: 271–5. doi: 10.22034/apjcp.2017.18.1.271 GuoAY ZhaiK XuJL HuJL GaoL Identification of a low-frequency mis-sense variant in E2F transcription factor 7 associated with colorectal cancer risk in a chinese population Asian Pac J Cancer Prev 2017 18 271 5 10.22034/apjcp.2017.18.1.271 Open DOISearch in Google Scholar

44. Chen J, Etzel CJ, Amos CI, Zhang Q, Viscofsky N, Lindor NM, et al. Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. Cancer Causes Control 2009; 20: 1769–77. doi: 10.1007/s10552-009-9416-x ChenJ EtzelCJ AmosCI ZhangQ ViscofskyN LindorNM Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome Cancer Causes Control 2009 20 1769 77 10.1007/s10552-009-9416-x Open DOISearch in Google Scholar

45. Gołąbek K, Biernacki K, Gaździcka J, Strzelczyk JK, Miśkiewicz-Orczyk K, Krakowczyk Ł, et al. Selected E2F2 polymorphisms in oral and oropharyngeal squamous cell carcinoma. BioMed Res Int 2021; 2021: 8098130. doi: 10.1155/2021/8098130 GołąbekK BiernackiK GaździckaJ StrzelczykJK Miśkiewicz-OrczykK KrakowczykŁ Selected E2F2 polymorphisms in oral and oropharyngeal squamous cell carcinoma BioMed Res Int 2021 2021 8098130 10.1155/2021/8098130 Open DOISearch in Google Scholar

46. Lu M, Liu Z, Yu H, Wang LE, Li G, Sturgis EM, et al. Combined effects of E2F1 and E2F2 polymorphisms on risk and early onset of squamous cell carcinoma of the head and neck. Mol Carcinog 2012; 51(Suppl 1): E132–41. doi: 10.1002/mc.21882 LuM LiuZ YuH WangLE LiG SturgisEM Combined effects of E2F1 and E2F2 polymorphisms on risk and early onset of squamous cell carcinoma of the head and neck Mol Carcinog 2012 51 Suppl 1 E132 41 10.1002/mc.21882 Open DOISearch in Google Scholar

47. Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M, et al. Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer 2009; 101: 1461–8. doi: 10.1038/sj.bjc.6605284 CunninghamJM VierkantRA SellersTA PhelanC RiderDN LiebowM Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis Br J Cancer 2009 101 1461 8 10.1038/sj.bjc.6605284 Open DOISearch in Google Scholar

48. Li Y, Sturgis EM, Zhu L, Cao X, Wei Q, Zhang H, et al. E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog 2017; 56: 1335–43. doi: 10.1002/mc.22595 LiY SturgisEM ZhuL CaoX WeiQ ZhangH E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx Mol Carcinog 2017 56 1335 43 10.1002/mc.22595 Open DOISearch in Google Scholar

49. Scarpulla RC. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann N Y Acad Sci 2008; 1147: 321–34. doi: 10.1196/annals.1427.006 ScarpullaRC Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator Ann N Y Acad Sci 2008 1147 321 34 10.1196/annals.1427.006 Open DOISearch in Google Scholar

50. Bhawe K, Roy D. Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression. Cell Oncol (Dordr) 2018; 41: 465–84. doi: 10.1007/s13402-018-0395-3 BhaweK RoyD Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression Cell Oncol (Dordr) 2018 41 465 84 10.1007/s13402-018-0395-3 Open DOISearch in Google Scholar

51. Crocco P, Montesanto A, Passarino G, Rose G. Polymorphisms falling within putative miRNA target sites in the 3′UTR region of SIRT2 and DRD2 genes are correlated with human longevity. J Gerontol A Biol Sci Med Sci 2016; 71: 586–92. doi: 10.1093/gerona/glv058 CroccoP MontesantoA PassarinoG RoseG Polymorphisms falling within putative miRNA target sites in the 3′UTR region of SIRT2 and DRD2 genes are correlated with human longevity J Gerontol A Biol Sci Med Sci 2016 71 586 92 10.1093/gerona/glv058 Open DOISearch in Google Scholar

52. Qu L, He B, Pan Y, Xu Y, Zhu C, Tang Z, et al. Association between polymorphisms in RAPGEF1, TP53, NRF1 and type 2 diabetes in Chinese Han population. Diabetes Res Clin Pract 2011; 91: 171–6. doi: 10.1016/j.diabres.2010.11.019 QuL HeB PanY XuY ZhuC TangZ Association between polymorphisms in RAPGEF1, TP53, NRF1 and type 2 diabetes in Chinese Han population Diabetes Res Clin Pract 2011 91 171 6 10.1016/j.diabres.2010.11.019 Open DOISearch in Google Scholar

53. Liu Y, Niu N, Zhu X, Du T, Wang X, Chen D, et al. Genetic variation and association analyses of the nuclear respiratory factor 1 (nRF1) gene in Chinese patients with type 2 diabetes. Diabetes 2008; 57: 777. doi: 10.2337/db07-0008 LiuY NiuN ZhuX DuT WangX ChenD Genetic variation and association analyses of the nuclear respiratory factor 1 (nRF1) gene in Chinese patients with type 2 diabetes Diabetes 2008 57 777 10.2337/db07-0008 Open DOISearch in Google Scholar

54. Permuth-Wey J, Chen YA, Tsai YY, Chen Z, Qu X, Lancaster JM, et al. Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2011; 20: 1131–45. doi: 10.1158/1055-9965.Epi-10-1224 Permuth-WeyJ ChenYA TsaiYY ChenZ QuX LancasterJM Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk Cancer Epidemiol Biomarkers Prev 2011 20 1131 45 10.1158/1055-9965.Epi-10-1224 Open DOISearch in Google Scholar

55. Shen S, Wei Y, Li Y, Duan W, Dong X, Lin L, et al. A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival. NPJ Precis Oncol 2021; 5: 39. doi: 10.1038/s41698-021-00182-3 ShenS WeiY LiY DuanW DongX LinL A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival NPJ Precis Oncol 2021 5 39 10.1038/s41698-021-00182-3 Open DOISearch in Google Scholar

56. Wang X, Fei F, Qu J, Li C, Li Y, Zhang S. The role of septin 7 in physiology and pathological disease: a systematic review of current status. J Cell Mol Med 2018; 22: 3298–307. doi: 10.1111/jcmm.13623 WangX FeiF QuJ LiC LiY ZhangS The role of septin 7 in physiology and pathological disease: a systematic review of current status J Cell Mol Med 2018 22 3298 307 10.1111/jcmm.13623 Open DOISearch in Google Scholar

57. Zhu C, Hu H, Li J, Wang J, Wang K, Sun J. Identification of key differentially expressed genes and gene mutations in breast ductal carcinoma in situ using RNA-seq analysis. World J Surg Oncol 2020; 18: 52. doi: 10.1186/s12957-020-01820-z ZhuC HuH LiJ WangJ WangK SunJ Identification of key differentially expressed genes and gene mutations in breast ductal carcinoma in situ using RNA-seq analysis World J Surg Oncol 2020 18 52 10.1186/s12957-020-01820-z Open DOISearch in Google Scholar

58. Ye L, Wang F, Wu H, Yang H, Yang Y, Ma Y, et al. Functions and targets of miR-335 in cancer. Onco Targets Ther 2021; 14: 3335–49. doi: 10.2147/ott.S305098 YeL WangF WuH YangH YangY MaY Functions and targets of miR-335 in cancer Onco Targets Ther 2021 14 3335 49 10.2147/ott.S305098 Open DOISearch in Google Scholar

59. Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K, et al. Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat 2011; 127: 549–54. doi: 10.1007/s10549-010-1244-x YangR DickM MarmeF SchneeweissA LangheinzA HemminkiK Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk Breast Cancer Res Treat 2011 127 549 54 10.1007/s10549-010-1244-x Open DOISearch in Google Scholar